Beyond pain management:  A primer for providing quality end-of-life care by Tomko, Linda P. & Maxwell, Terri L.
Thomas Jefferson University
Jefferson Digital Commons
Department of Family & Community Medicine
Faculty Papers Department of Family & Community Medicine
January 2001
Beyond pain management: A primer for providing
quality end-of-life care
Linda P. Tomko
Jefferson Medical College, linda.tomko@jefferson.edu
Terri L. Maxwell
Jefferson Medical College, Terri.Maxwell@jefferson.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/fmfp
Part of the Family Medicine Commons, and the Translational Medical Research Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Family & Community Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Tomko, Linda P. and Maxwell, Terri L., "Beyond pain management: A primer for providing quality
end-of-life care" (2001). Department of Family & Community Medicine Faculty Papers. Paper 2.
http://jdc.jefferson.edu/fmfp/2
The Internet Journal of Family Practice TM
Beyond Pain Management: A Primer For 
Providing Quality End-of-life Care
Linda P. Tomko MD
Instructor, Assistant Medical Director
Department of Family Medicine
Jefferson Hospice
Jefferson Medical College, Jefferson Health System
Terri L. Maxwell RN, MSN, AOCN
Executive Director, Center for Palliative Care
Department of Family Medicine
Jefferson Medical College
Citation: 
Linda P. Tomko & Terri L. Maxwell: Beyond Pain Management: A Primer For Providing 
Quality End-of-life Care: The Internet Journal of Family Practice. 
2001; Volume 1, Number 2.
Abstract
Providing excellent care for a dying patient is something all patients deserve. Hospices 
and palliative care centers exist in many areas to aid primary care physicians and patients 
through this difficult time. It is important to remember that most patients want to prepare 
for death, if at all possible. Everyone does this in his or her own way, but oftentimes 
concern about pain and symptom management interfere with this very involved and 
valuable process. Being prepared to treat these symptoms as well as addressing your 
patient's emotional needs is imperative. Referral to a hospice, if possible, will only 
strengthen the support available to the patient, the family, and you, the primary care 
physician. In the end, there is much that we have to offer a dying patient. Efforts should 
not stop because the illness cannot be cured. So much can happen to someone in the 
window of time between terminal diagnosis and death. Making this period one in which a 
person is as mentally clear, physically comfortable, and symptom free for as long as 
possible is a goal that is worthy of our efforts.
Introduction
“I’m sorry, but there is nothing more that we can do.”
Imagine what it must be like to hear those words: so sobering, so isolating, so final, and 
so untrue. Yet they are spoken and heard far too often in physician offices and hospitals. 
These words have become a cliché in modern lingo, spoken by movie and TV doctors for 
dramatic effect. Today, with the advances in palliative care, these words never need to be 
spoken to a patient. Primary care physicians now realize there is much that can be offered 
to the patient with advanced disease, and that providing quality and comprehensive care 
to the dying patient is a skill worth knowing and knowing well.
Accepting death as a natural outcome of illness is antithetical to the way thousands of 
doctors are trained. Physicians and patients expect physicians to cure and consider death 
a failure. Pick a physician at any level of training. Chances are that he or she is not only 
reluctant to speak to a dying patient about death, but is also inaccurate in his/her 
prognosis. Oftentimes, physicians are overly optimistic about prognoses and patients end 
up being referred to hospice or palliative care teams much too late. 1 The SUPPORT 
Study (Study to Understand Prognosis and Preference for Outcomes and Risks of 
Treatments) revealed that dying patients also experience considerable suffering and are 
the victims of inappropriate use of medical resources. 2 Many people die long and painful 
deaths and receive unwanted, invasive medical attention. Some people die in a place 
where the fear of pain and the loss of control and dignity become a burden to them and 
their families. 3 It doesn’t have to be this way. The ideal environment would be one in 
which the patient and family would be able to plan ahead for the death and where the 
center of control is wrested back from the medical sphere and returned to the patient. 
Now more than ever, patients have the chance to spend their dying days cared for by a 
hospice or palliative care team. These teams attempt to provide a secure environment for 
the patient where symptoms are expertly managed. Such teams provide medical, 
emotional and spiritual support to the patient as well as his or her entire family through a 
comprehensive, interdisciplinary approach to care. Hospice/palliative care teams typically 
include nurses, home health aides, social workers, pastoral care workers, administrators, 
and physicians. Satisfaction at the end of life has been positively correlated with hospice, 
where the emphasis is placed on palliation. However, only about 20% of patients who die 
in the United States receive hospice care. The admission criterion of a 6-month prognosis 
or less has been identified as a barrier to hospice referrals. This is in part related to the 
difficulty in accurately predicting prognosis and in part related to the discomfort 
surrounding discussing prognosis with patients. 4
Becoming a physician capable of providing for the needs of a dying person requires 
accepting the inevitability of death in some circumstances. Prognosis needs to be 
objectively and accurately assessed and then shared with the patient and patient’s family 
in a compassionate, clear, and supportive manner. Too often, physicians have inadequate 
skills to address these conversations. A study by Barzansky, Veloski, Miller, and Jonas 
reviewed the history and status of end-of-life care in US medical schools in 1999 and 
found that while most medical schools reported that they include end of life care in their 
curriculum, many medical students describe their education as inadequate. 5 Medical 
schools have not included communication skills or palliative care concepts in their 
curriculum and there is an absence of explicit prognostication in medical textbooks. 6
Physicians often fear that discussing a poor prognosis or identifying a condition as 
terminal will cause emotional pain and loss of hope and when patients suffer emotionally, 
physicians often do not know how to respond. 7 Others view death as a failure or feel 
threatened by such discussions. 8 Latimer describes ethical communication at this time as 
consisting of “truth with tenderness.” 9 Information about prognosis should be as accurate 
as the circumstances allow and conveyed in a language that is understandable to the 
patient. Euphemisms and medical jargon should be avoided and time should be allowed 
to answer any questions that the patient may have. The patient should be given referrals 
to the palliative care team if one is available and desired. Lastly, the physician should be 
sure that the patient has a way to reach him or her for questions that are thought of later.9
An important aspect of palliative care is establishing the goals of care. Discussions 
surrounding goals for care should include clear information about treatment choices, 
including measures to actively support the patient in palliative care. Once a choice has 
been made, it should be repeated back to the patient for verification. An important care 
goal is having the patient and family realize their important role in working together with 
the healthcare team. A pathway for patient support in times of uncertainty should be 
identified. This includes assisting the patient in writing an advance directive and durable 
medical power of attorney, as well as helping to iron out complicated family dynamics. 
Another important step in becoming a physician who provides comprehensive, quality 
care for the dying patient is gaining expertise in managing such patients. Recent studies 
have shown that three out of every four patients dying from cancer experience significant 
periods of pain. 10 Appropriately and expeditiously managing pain in the dying patient 
includes the skillful use of opioids in these circumstances. Many articles have been 
written on managing pain in the dying patient. Several references are provided at the end 
of this article. 
Providing comprehensive care to the dying patient also means that primary care 
physicians should be familiar with methods of treating distressing symptoms other than 
pain. These symptoms; dyspnea, anxiety, depression, gastrointestinal symptoms, 
anorexia/cachexia, delirium and asthenia are a common to the dying experience and are 
too often inadequately or poorly managed. The remainder of this article will focus on the 
medical management of these symptoms.
Dyspnea
Shortness of breath is a terrifying and common symptom in the dying patient. Dyspnea 
can frighten patients and family members to the extent that the patient may be sent to the 
hospital for airway or ventilatory support even if the original plan and goals of treatment 
did not call for such action. Although the rate at which dyspnea occurs has not been well 
documented, it is believed to occur with moderate severity in one-quarter of all dying 
patients. 11 The physician and team caring for the dying individual need to have a plan 
available for treating dyspnea because panic in the home is often and understandably the 
rule when someone is acutely short of breath. 
Dyspnea can be defined as an uncomfortable awareness of one’s breathing. 12 Dyspnea is 
now recognized as a combination of many factors including disordered breathing due to a 
multitude of medical conditions, psychological issues, and functional problems. 13 Like 
pain, people with comparable degrees of functional lung impairment may experience 
varying degrees of dyspnea. Dyspnea is a subjective phenomenon, which is best 
measured by patient self-report. The objective signs many times do not match the 
patient’s perceptions of dyspnea and other functional limitations. The treatment of 
dyspnea should address the underlying cause, taking into account the life expectancy, 
invasiveness, and potential complications of the therapeutic interventions. 14 Since 
emotional events, such as anxiety, often play an important role in engendering dypsnea, 
the goals of treatment are usually two-fold. First, to determine the underlying cause and 
treat it if possible, and secondly, to treat the patient so that the relief of the symptom is 
the goal rather than treating a lab or test value. Pulseoximetry is not a reliable indication 
of dyspnea. The patient’s ease of breathing often serves as the best marker. The goal in 
the treatment of shortness of breath in the dying patient is to improve the subjective 
symptoms with the treatments available and to keep the patient as comfortable as possible 
using the patient’s own standard for our evaluation.
The standards for treatment of dyspnea have been oxygen, opioids, and benzodiazepines. 
Oxygen is a great comfort to many people who are short of breath. A number of studies 
have revealed it to be a great support for the patient and family. 15 Its benefits for some 
people go beyond an objective measure such as an increase in PO2—it provides them 
with a level of comfort and a sense of freedom from fear of suffocation. Unless 
contraindicated by diagnosis, oxygen should be available to the patient who is short of 
breath. 
Opioids have the ability to decrease the physiologic need for oxygen. For many years, 
palliative care teams in Britain and some in the US have used nebulized opioids, 
believing that local site treatment was preferable. Recent studies, however, have revealed 
that nebulized opioids most likely have little effect beyond that of placebo and that 
nebulized saline itself can be effective for treatment for dyspnea. 16 When first starting an 
opioid, it is often preferable to begin with a concentrated, short-acting medication such as 
Oxyfast or MSIR. 5 to10 mg of this type of medication in the opioid naïve patient is often 
sufficient to provide relief when combined with oxygen and other therapies for the 
underlying causative condition. 
Benzodiazepines have long played a role in the treatment of dypsnea. Experts in 
palliative care are split in how and if to prescribe a benzodiazepine for dyspnea. One 
camp believes that the medication is necessary to treat the anxiety, which inexorably 
accompanies any attack of dyspnea.1 Others believe that benzodiazepines have limited 
benefits in patients that do not have panic/anxiety periods and are being used too 
frequently and unnecessarily for shortness of breath.14 Benzodiazepines are best used to 
treat the anxiety associated with dyspnea in combination with an opioid. 
When treating shortness of breath, take into consideration the underlying disease. Patients 
with airflow obstruction due to chronic obstructive pulmonary disease, for instance, will 
benefit from treatment with beta-agonists and should be continued on their standing doses 
of inhalers or nebulized medications. 
Patients suffering from end stage lung disease may also have problems handling 
secretions. Often a dose of levsin or scopalamine can bring this under control, especially 
if used in conjunction with the appropriate adjunct medications
Anxiety
Anxiety is common in the dying, as patients face their fears and concerns about their 
impending death. However, anxiety is not a normal, inevitable consequence of dying and, 
when present, should be managed aggressively. If anxiety is accepted as a normal part of 
the dying process, then a person is left to suffer with an extremely painful mental and 
emotional experience without the aid of medication, personal attention, or therapy. 
Anxiety may also mask incipient medical complications such as pain, internal injuries, or 
pulmonary embolism. Risk factors for anxiety include organic mental disorders, 
concurrent life events or social difficulties, lack of support and understanding from one’s 
family and friends, and apprehension and worry. 17
The treatment of anxiety often requires a combination of psychosocial support and 
pharmacotherapy. Providing support and a safe environment for discussing one’s 
concerns and fears is very important. Sometimes a simple question, “What are you 
worried about?” allows a patient to discuss his or her concerns, which may be therapeutic 
unto itself. 
If pharmacotherapy is required, benzodiazepines are generally the medication of choice. 
The benzodiazepines are chosen based upon the desired half-life. The longer half-life 
medications have a more sustained effect, but may accumulate and are not recommended 
in the elderly or those with hepatic impairment. Any of these agents needs to be used 
with caution, since delirium can be readily induced by a combination of drugs and illness 
in dying patients. Short-acting benzodiazepans (lorazepam, oxazepam) are appropriate to 
use first line, but if they are not working or cannot be used, major tranquilizers such as 
haloperidol may be helpful. When initiating haloperidol, always begin with small doses: 
1.5 to 5 mg every six to eight hours as needed. Patients should be closely monitored when 
taking such medication. If anxiety persists, adjunctive therapies such as acupuncture and 
guided imagery with relaxation therapy may also help. In cases of intractable anxiety, a 
psychiatric consultation utilizing new drugs and therapies may prove beneficial. 
Depression
Although sadness is common in patients with life-threatening disease, it is a myth that 
feeling helpless, hopeless, and depressed are inevitable consequences of advanced illness. 
Sadness generally responds to supportive interventions. Depression, on the other hand, is 
a pathologic state marked by greater cognitive impairment and generally requires more 
aggressive therapy. 
Diagnosis can be difficult, but several studies have revealed that merely asking the 
patient “Are you depressed?” can actually identify people who otherwise might not have 
received therapy. 18 Depression should be considered if a person has persistent periods of 
intense sadness and anxiety accompanied by depressive symptoms for greater than a few 
days or weeks.
It is well known that the most frequently used drugs for depression, the SSRIs, take 
several weeks to develop a therapeutic effect. Occasionally, someone does not have 
weeks to wait for a significant improvement. More and more physicians are discovering 
the benefits of a class of drugs called psychostimulants (dexamphetamine and 
methlyphenidate). They are safe and effective and their rate of onset of action is very fast.
19 Oftentimes, these medications, when used at low dose and with close supervision, can 
greatly improve the quality of a patient’s last few months. The improvement in energy,
concentration, and mood may last until the longer acting drugs are able to take effect. 
One should not discount the importance of therapy and counseling in the treatment of the 
depressed, dying patient. While group therapy may sometimes be helpful, almost any 
intervention may help the patient to feel better and to be better prepared to cope with 
daily stressors.
Gastrointestinal Complaints
Nausea can be a frequent and unwanted companion of a dying person. While frequently 
related to medication such as chemotherapy and opioids, it is important to attempt to 
discover the etiology of the nausea to see if specific, targeted therapies can improve 
symptoms. The most common causes of nausea include autonomic dysfunction, 
gastroparesis, and opioid analgesics. Opioids cause nausea in several ways, including 
delayed gastric emptying time, vestibular stimulation, and constipation. 20 Treatment of 
nausea depends, in a large part, upon the presumed underlying cause. When the 
mechanism or cause of the nausea is understood, the treatment can be tailored with 
improved success in controlling the symptom. There are many drugs used to treat nausea, 
but for patients without bowel obstruction, metoclopramide is beneficial because it acts 
centrally and aids in gastric emptying. 21 When obstruction is present and increased 
intestinal and gastric secretions accumulate, medications such as octreotide will help treat 
the accompanying nausea. 22 Haloperidol and prochlorperazine act centrally to decrease 
nausea and are frequently also used. A combination of approaches is necessary in some 
patients.
Delirium 
Perhaps one of the most difficult symptoms to manage in the dying patient is delirium. It 
is often as difficult to diagnose as it is to treat, but it remains the most frequent 
neuropsychiatric disorder that affects the dying. Indeed, according to many studies, most 
people are in a delirious state when they die. 23 Delirium is a state of decreased cognitive 
abilities. Delirium usually has a quick onset and in contrast to dementia, is considered to 
be a potentially reversible process. Patients often exhibit changes in their sleep and wake 
cycles and may experience a fluctuating level of consciousness. Delirium can be divided 
into two categories: hypoactive and hyperactive. In the hypoactive phase patients may 
become more withdrawn, experience difficulty in attending to tasks, or have acute 
problems with their memory. In the “hyperactive” phase of delirium, patients may 
experience psychosis with delusions, paranoia, and hallucinations. The differential 
diagnosis for delirium is extensive. It includes adverse effects of medications (narcotics, 
benzodiazepines, coriticosteroids and anti-cholinergic agents), infection, metabolic 
problems, dehydration, direct effects of the disease on the central nervous system, and 
organ failure. Patients with delirium have a much higher morbidity rate than those 
without delirium. 24
In any patient showing acute onset of agitation, impaired cognitive function, altered 
attention span, or fluctuating level of consciousness, a diagnosis of delirium should be 
considered. A mini-mental exam is helpful to document the change in mental capacity, 
and a search for the etiology of the delirium should be undertaken. If a diagnosis for the 
change is found (i.e. a UTI), this should be treated if desired so by the patient and/or the 
patients’ s family. Approximately 30% of people with delirium will experience 
improvement back to baseline with treatment of the immediate cause. 25 Unfortunately, in 
the majority of those affected, an etiology will not be found and treatment will not 
improve their outcome. 
Since the cause of delirium is often multifactorial or elusive, and the work-up may be 
limited by the setting or uncomfortable for the patient, the focus of the care is often 
patient comfort. If someone is agitated, “sundowning,” or delusional, the first line of 
therapy will involve using neuroleptics. Neuroleptics, such as low-dose haldol, allow the 
person to think more clearly and to become less agitated with some mild sedation. It is 
important to remember when using any drug; you want to begin with the smallest dose 
possible for the situation and the patient. Often 0.5mg to 1mg of haloperidol is sufficient 
to relieve the mental anguish, but this may need to be increased. Other medications that 
can be used include respiridone, which has an improved side effect profile, but is still 
investigational in this population.
“Terminal anguish,”12 is a combination of delirium, anxiety, and debilitation that can 
occur shortly before death. It can be extremely frightening for the patient and extremely 
disturbing to the family. Keeping the patient comfortable, calm, and sedated if necessary 
should be the major goal of treatment. Pain medication and anxiolytics should be used. 
Preparatory discussions with family members may be one way to make this time less 
difficult for everyone involved. 
Cachexia/Anorexia
Perhaps one of the most physically remarkable aspects of the dying process is the weight 
loss and related change in appearance that many people experience. This cachetic 
appearance is often alarming and is again usually multifactorial in cause. Anorexia and 
cachexia seem to travel hand in hand. The physical processes that lead to weight loss 
include lipolysis, loss of viseral and skeletal protein mass, and profound anorexia. 26
Weight loss decreases a person’s chance of survival and has a terrible effect on the 
morale and psyche of the patient and their loved ones. Aggressive efforts to feed a dying 
patient (tube feeding, TPN) have not shown significant improvement or extension of 
patient survival. 27
The treatment of anorexia should be patient driven. If a person requires encouragement 
for feeding and is still capable of eating, they should be offered food that they enjoy and 
find appetizing. Pharmacologic measures for therapy are slowly expanding and include 
corticosteroid and progestational drugs such as megestrol. Corticosteroids have been 
found to have a limited efficacy for management of this symptom, although they can help 
alleve asthenia. The optimal doses for Megace and the like are relatively high: between 
480 to 800 mg. In the dying patient, doses in the 480 mg range may be helpful in 
stimulating appetite without associated weight gain. Studies performed on these drugs in 
dying patients report improved appetite, less fatigue, and greater sense of well being. 28
The physician and patient should treat these drugs with the respect that they deserve 
however, and one must be cautious when using them. The progestation agents can be first 
line, but it is important to know that if they are stopped too quickly, peripheral edema, 
thromboembolic events and vaginal bleeding, while rare, are potential side effects. 
Agents under investigation for the treatment of anorexia include thalidomide and omega 
3 fatty acids.
Asthenia 
Another extremely common symptom in the dying patient is asthenia. Although 
especially prevalent in cancer patients, asthenia can plague almost any person as they 
approach the end of their life. Brea describes asthenia as a profound tiredness after one 
performs usual or minimal effort. It is also characterized by generalized weakness. It is 
estimated that full nine out of ten advanced cancer patients will experience asthenia as 
their disease progresses. The cause is felt to be multifactorial and is well correlated with 
anorexia. Tumor effects such as tumor mediated products, anemia, chronic infection and 
paraneoplastic syndromes often play a role in the development of asthenia.7 Interestingly, 
a study in the Netherlands, where euthanasia is permitted, described asthenia, or 
“weariness with life” as a frequent contributor to the decision to end one’s life. 29
Treatment is based initially upon determining if any specific causes exist. Depression 
should be treated if present. Infection and anemia should be treated, if the patient desires. 
If these measures are unsuccessful, non-pharmacologic management should be initiated. 
Consultations for energy conservation techniques with physical and occupational 
therapists should be explored and activities of daily living should be modified. It further 
improvement is still needed, pharmacologic measures should be considered including 
corticosteroids such as decadron or medrol or methamphetamines such as ritaline. 30
Often, these medications have a limited period of effectiveness in a particular patient, but 
the quality of time afforded the patient is well worth the trial. 
The end of life...how do you know when 
it’s happening
Families and patients often search for someone to give them absolutes. When will he die? 
Will it be quick? Will it be painful? While we can attempt to control the symptoms, we 
cannot always predict the pattern. While it is probably not advisable to give definitive 
prognoses (e.g. “She’ll die before year’s end”) you can sometimes help patients and their 
families by informing them when death appears imminent. Certainly, many people die 
without giving us these clues to pass on to the family, but when they are present, the 
family should be notified. Signs that the end may be approaching include: terminal 
breathing patterns such as Cheyne-Stokes respirations, decreased or non-existent urine 
output, inability to take in food and liquid in a person who has no feeding tube, and 
declining cognitive status. Talking to family members, letting them know how the pattern 
has changed, and giving them the opportunity to be with their loved one and say goodbye 
or “I love you” is an important role that is often overlooked, especially if the patient is 
not enrolled in a palliative care or hospice program. 
Conclusions
Providing excellent care for a dying patient is something all patients deserve. Hospices 
and palliative care centers exist in many areas to aid primary care physicians and patients 
through this difficult time. It is important to remember that most patients want to prepare 
for death, if at all possible. Everyone does this in his or her own way, but oftentimes 
concern about pain and symptom management interfere with this very involved and 
valuable process. Being prepared to treat these symptoms as well as addressing your 
patient’s emotional needs is imperative. Referral to a hospice, if possible, will only 
strengthen the support available to the patient, the family, and you, the primary care 
physician. 
In the end, there is much that we have to offer a dying patient. Efforts should not stop 
because the illness cannot be cured. So much can happen to someone in the window of 
time between terminal diagnosis and death. Making this period one in which a person is 
as mentally clear, physically comfortable, and symptom free for as long as possible is a 
goal that is worthy of our efforts. 
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